Multiple Myeloma Coverage from Every Angle

Alexander M. Lesokhin, MD, on Initial Safety Data for Elranatamab in Multiple Myeloma

Posted: Friday, July 8, 2022

Alexander M. Lesokhin, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, discusses phase II findings from the MagnetisMM-3 trial, which tested once-weekly elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma who had received no prior BCMA-targeted treatment. This agent, with a two step–up priming regimen, appeared to be well tolerated.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.